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SUMMARY 
Cardiogenic shock is common in patients with cardiac or extra-cardiac filling 
disorders. Cardiac tamponade is a life-threatening medical emergency situation where the 
pump failure is caused by effusions of blood, pus or fluids. Drainage of the pericardial sac 
through pericardiocentesis or surgical pericardiotomy is the first choice of treatment, but 
supportive medical therapy should be considered following or parallel to the relief of the 
intrapericardial pressure, with a view to avoiding low flow-induced peripheral complications. 
Moreover, it is recognized that splanchnic macro- and microcirculatory dysfunctions are 
linked to local and systemic inflammatory activation, and the increased afterload may 
subsequently worsen the hypoperfusion of the peripheral organs and result in an increased 
oxygen demand of the myocardium. The general purpose of the research reported in the 
dissertation was to characterize the major components of the pro-inflammatory profile of the 
post-tamponade phase, in association with the changes in overall haemodynamics, and to 
outline a possible therapeutic route to reverse the cardiac tamponade-caused detrimental 
consequences in a clinically relevant large animal model. We considered that a better 
understanding of the elements of these mechanisms may lead to new prospects for 
interventions designed to dampen or reverse the secondary detrimental consequences of 
cardiac failures. 
In Study I, we hypothesized that acute failure of the myocardial pump function is 
accompanied by significant inflammatory activation, which can play important roles in further 
gastrointestinal complications. We investigated the immediate effects of cardiac tamponade 
on the systemic and peripheral circulations and characterized the major components of the 
pro-inflammatory profile of the post-tamponade phase, in association with the changes in 
overall haemodynamics. We identified characteristic macrohaemodynamic changes, together 
with apparent signs of a splanchnic inflammatory reaction after relief of the tamponade. The 
evidence further suggests that the activation of the complement and endothelin systems may 
be significant components of the inflammatory cascade that is activated in porcine pericardial 
tamponade. It iscurrently widely accepted that inflammatory activation plays a decisive role 
in low-flow conditions, although the potential of ‘anti-inflammatory’ compounds to prevent 
or cure hypoperfusion-induced in vivo processes is very limited. With this background, we 
hypothesized that early inhibition of complement C5a might well reduce the adverse cardiac 
and inflammatory consequences after relief of the cardiac tamponade. In Study II, during the 
acute phase of cardiac tamponade in our clinically relevant large animal model we used a 
synthetic, antisense, 17 amino acid peptide acetylated at the N-terminal alanine (acetyl-
peptide-A - AcPepA). Previous studies have shown that this compound is capable of binding 
directly to C5a peptide. We hypothesized that, through this mechanism, AcPepA can 
influence the early cardiac and inflammatory changes, and the results furnished evidence that 
the administration of AcPepA significantly limits the extent of the cardiac dysfunction in this 
scenario. 
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1. INTRODUCTION 
1.1. Circulatory shock 
Maintenance of adequate perfusion of vital organs is critical for survival. Shock may 
be defined as a state in which profound and widespread reduction of tissue perfusion leads to 
reversible, and then, if prolonged, irreversible cellular injury. Since a reduction of tissue 
perfusion is a central issue, it is important to consider the factors that control this vital 
function. Organ perfusion is dependent on an appropriate perfusion pressure, which in turn is 
determined by two variables, the cardiac output (CO) and the systemic vascular resistance 
(SVR). The second critical determinant of arterial pressure, the CO, is the product of stroke 
volume (SV) and heart rate (HR). 
The classification of shock is usually based on the aetiology. Cardiogenic shock, 
extracardiac obstructive shock, hypovolaemic shock and distributive shock are major 
categories (Parrillo 1991). The final pathway leads to cell death, but some characteristics of 
shock are the same regardless of the underlying cause or pathogenesis. One common 
denominator of different forms of shock is a low CO. Patients with shock develop a severe 
decrease in CO and hence a low perfusion of vital organs. The survival depends on the correct 
early diagnosis and therapy. 
Two basic mechanisms can lead to a decrease of CO in shock: a failure of preload (i.e. 
a diminished venous return) in consequence of a decreased blood volume (in hypovolaemic 
shock) or a decrease in the efficiency of the pump function of the heart. The latter occurs in 
cardiogenic shock, in which the primary failure is myocardial rather than peripheral. This can 
arise after acute myocardial infarction or as a result of pericardial tamponade. In pericardial 
tamponade, compression of the atria and the right ventricle causes an acute rise in the 
pericardial pressure (by the accumulation of blood in the pericardial sac), which hinders the 
diastolic filling of the heart (Tyson et al. 1984), thereby leading to a decreased CO. 
1.2. Determinants of cardiac pump function 
The myocardial performance is dependent on the preload, afterload, (HR) and 
contractility, and is influenced by neurohormonal and local endothelial cell-derived factors. 
The cardiac pump function or performance depends on many parameters, which act in 
parallel, and normally exist to some degree. Examples of performance parameters include the 
CO, left ventricular (LV) SV, the rate of fibre shortening, the stroke work, the myocardial 
compliance and the ejection fraction. 
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1. The preload is a result of heterometric autoregulation. When the cardiac muscle is 
stretched, it tends to develop greater contractile tension on excitation (this is Starling's law of 
the heart). Thus, the SV tends to increase in proportion to the preload (diastolic filling). 
2. The afterload is determined by the total peripheral vascular resistance (TPVR). A sudden 
rise in afterload causes an immediate decrease in ejection fraction and a rise in end-systolic 
volume (ESV). The compensation can occur in two ways. An increased ESV coupled with a 
normal venous return leads to an elevated preload, and the SV is maintained by Starling's law. 
In addition, contractility may increase secondary to an increased coronary perfusion pressure, 
the Gregg effect (Anrep and Saalfeld 1933, Gregg 1963). Thus, small changes in afterload 
have a minimal steady-state effect on performance as measured via the SV or CO, despite a 
significant initial effect. 
3. HR increases are usually associated with small increases in contractile force. However, an 
increased HR is associated with a proportionally shorter diastolic filling time and for this 
reason the atrial contraction becomes far more important at high HR. It has been established 
that the heart contractility depends on increasing HR in most mammals. The ventricular 
myocardium has an inherent ability to increase its strength of contraction, independently of 
neurohormonal control, in response to an increase in contraction. In humans, this myocardial 
property causes the contractile force to rise, as the contraction frequency is increased from 60 
to about 180-200 beats min-1, and then to decline with further increase in frequency (the 
force-frequency relation) . 
4. Contractility is often defined as the intrinsic ability of a cardiac muscle fibre to contract at a 
given fibre length. Changes in the ability to produce force during contraction result from 
different degrees of binding between myosin and actin filaments. The degree of binding that 
occurs depends on the concentration of Ca2+ in the cell. The cytosolic Ca2+ level is the 
determinant of the involved myocardial fibre number in the contraction process and the 
maximum velocity of myocardial fibre shortening. An increased contractility, positive 
inotropic effect is reflected in a higher myocardial fibre shortening velocity with a higher 
cytosolic Ca2+ concentration in systole: more troponin is activated from higher levels of Ca2+ 
with more actin-myosin cross-bridges in unit time, and ultimately the myocardial fibre 
contraction is more extensive and faster. The performance improves at any given preload and 
afterload. 
Neural influences mean that the sympathetic discharge to the ventricles increases their 
contractility. Likewise, circulating epinephrine increases contractility. Other inotropic agents, 
such as Ca2+ sensitizers, phosphodiesterase inhibitors, cardiac glycosides, catecholamines and 
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endothelial cell-derived factors, also modify the myocardial contractility and/or Ca2+ 
availability. 
1.3. Analysis of cardiac function 
Examinations of cardiac contractility in clinical practice would be extremely 
beneficial, but at present direct measurement is not possible. In experimental practice, there 
few invasive techniques are available with which to evaluate or calculate this parameter. The 
end-systolic pressure-volume or pressure-diameter relationship is a fundamental description 
of systolic cardiac mechanics, with especial regard to the preload recruitable stroke work 
(PRSW) relationship. PRSW is another index of contractility, which is perhaps less 
influenced by other parameters. Each pressure-volume/diameter loop is derived by caval vein 
occlusion. The slope of the derived linear relationship is a measure of contractility 
independent of the preload and afterload (Molnár et al. 2011). 
In clinical practice, non-invasive measurements of LV dimensions, volumes, ejection 
fraction and other indices of the systolic and diastolic function can be carried out by 
ultrasound techniques. Transthoracic echocardiography has an important and established 
diagnostic role and has been used successfully to monitor segmental wall motion, ejection 
fraction, valvular function, and to measure cardiac cavities. The evaluation of the ejection 
fraction is important for risk stratification before any surgical intervention. However, the 
ejection fraction is influenced by preload and afterload alterations without any change in 
contractility. Depending on the loading conditions, hearts with a lower ejection fraction can 
produce a greater CO. Although roughly indicative of the cardiac reserve, the ejection fraction 
is an inconsistent marker of the overall cardiac function preoperatively. 
Assessment of the LV function includes linear measurements, such as the LV internal 
dimension in diastole and systole, from which parameters such as fractional shortening could 
be derived. Two-dimensional echocardiography allows area measurements and derived 
volume calculations (i.e. Simpson rule measurements). Once the systolic and diastolic 
volumes have been determined, the SV can be calculated. The forward CO then equals the 
product of HR and SV. Assuming the absence of a mitral or aortic insufficiency, this can 
represent the CO. The application of Doppler echocardiography provides information on 
systolic flow parameters, and more recently the diastolic function. Doppler techniques have 
several advantages: they are non-invasive and simple, and provide continuous data.. In 
contrast, they also have some important limitations, such as the relative inaccuracy (high 
inter/intraobserver variability) of the cross-sectional measurements in the LV outflow tract. 
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With the help of some sophisticated new methods, such as strain rate imaging, the 
ventricular function can be determined exactly, but from a practical point of view it is rather 
complicated. Another new method is automated endocardial border definition, used for 
automatic quantification of the instantaneous LV volume. The SV and ejection fraction can be 
calculated from the maximum and minimum volumes. A further refinement of this method in 
combination with the instantaneous determination of systolic pressure is that it can provide 
load-independent information regarding ventricular contractility through the creation of a 
pressure-volume loop (Gorcsan et al. 1994), although its routine use during the operation and 
subsequently in the intensive care unit is limited. 
There are two prevalent invasive techniques in clinical practice, for the measurement 
and calculation of the preload and CO parameters by a thermodilution method. One of these 
techniques, which applies the pulmonary artery (Swan-Ganz) catheter, has been used for over 
20 years. Pulmonary artery thermodilution and the subsequent clinically established 
transcardiopulmonary thermodilution technique allow the measurement not only of the CO, 
but also of several other parameters reflecting the right (RV) and the biventricular function. 
Pulmonary artery thermodilution permits the measurement and calculation of the RV ejection 
fraction, the RV stroke volume, and the RV end-diastolic volume (Trepte et al. 2011). With 
the development of additional facilities, and particularly the continuous measurement of CO, 
the pulmonary artery catheter remains the mainstay in the bedside monitoring of myocardial 
performance in critically ill patients. 
Another invasive technique is the Pulse Contour Cardiac Output (PiCCO) system, 
which uses volumetric, transcardiopulmonary thermodilution. This technique is 
methodologically comparable and has been described as being a reliable and less invasive 
method for the measurement of CO (Reuter et al. 2010). It further enables an assessment of 
the global ejection fraction (GEF), describing the ratio of the SV to the global end-diastolic 
volume (GEDV). For the calculation of GEF, the SV is multiplied by 4 on the assumption that 
the GEDV represents the volume of all four heart chambers (GEF = 4 x SV/GEDV). The 
main advantages of the PiCCO system are the online function and the possibility of pulse 
contour analysis. A combination of the pulse contour CO and volumetric ejection fraction 
monitoring system permits calculation of the right heart and left heart end-diastolic volumes 
(RHEDV and LHEDV) (Végh et al. 2009). 
Less invasive methods for continuous and rapid perioperative monitoring are clearly 
needed to detect changes in central haemodynamics in order to optimize the haemodynamic 
performance and oxygen delivery. A promising method is an ultrasound-based technique for 
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the measurement of blood flow velocity and aortic diameter simultaneously in the descending 
aorta, with the use of transoesophageal echocardiography with a probe containing two 
ultrasound transducers (Odenstedt et al. 2001). 
1.4. Cardiac tamponade and its circulatory effects 
Cardiogenic shock may occur in patients with cardiac or extracardiac filling disorders 
such as cardiac tamponade (Topalian et al. 2008, Bodson et al. 2011). Cardiac tamponade is a 
typical cause of obstructive shock. It is defined by an acute circulatory failure secondary to 
compression of the heart chambers by a pericardial effusion. Tamponade is a life-threatening 
condition that is diagnosed clinically by an elevated jugular venous pressure, hypotension and 
pulsus paradoxus in the setting of a pericardial effusion. The diagnosis is usually easy if 
shock is present, but it may be difficult if the effusion develops without obvious circulatory 
failure. Knowledge of the pathophysiology and the echocardiographic characteristics of this 
disease is therefore fundamental. 
The incidence of cardiac tamponade is poorly documented. Numerous epidemiological 
studies have examined patients suffering from a pericardial effusion without focusing on 
tamponade. Interestingly, it was observed in a retrospective study of more than 10000 
ambulatory patients without previous pericardial disease that the existence of a small 
pericardial effusion on transthoracic echocardiography was associated with an increased 1-
year mortality rate from 11% to 26% (Mitiku and Heidenreich, 2011). 
Studies establishing the cause of pericardial effusion have yielded mixed results, 
probably due to the different diagnostic techniques applied. In a single centre study, 106 
patients were hospitalized for a large pericardial effusion, defined by a thickness greater than 
or equal to 20 mm in diastole, with or without a syndrome of cardiac tamponade; the causes 
found were cancer (36%), idiopathic (30%), infection (21%), myxoedema (8%), autoimmune 
diseases and vasculitis (5%). The reported incidence of acute pericardial tamponade is 
approximately 2% of penetrating trauma. In emergency situations, a haemopericardium is 
frequently encountered in patients with ascending aorta dissection or ventricular rupture 
following infarction. After cardiac surgery, the development of a pericardial haematoma 
behind the right atrium is a common cause of shock. However, its diagnosis may be difficult 
and requires transoesophageal echocardiography (Bodson et al. 2011). The increasing number 
of cardiac surgical interventions has resulted in a subsequent elevation in the overall number 
of iatrogenic pericardial tamponades. Further potential causes of cardiac perforation include 
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central line placement, pacemaker insertion, cardiac catheterization and electrophysiological 
ablation procedures (Valley and Fly, 2007). 
A raised intrapericardial pressure can occur by three main mechanisms: increased fluid 
within the intrapericardial space (pericardial tamponade), an increased volume of the cardiac 
chambers (cardiac diseases), or an increased stiffness of the pericardium (constrictive 
pericarditis). In the normal situation, the pericardium has a small capacitance reserve that will 
accommodate only a small increase in cardiac chamber size and/or pericardial fluid volume 
(approximately 150-250 mL) before a significant increase in the pericardial pressure 
(Goldstein 2004). 
The acute rise in pericardial pressure compresses the atria and the right ventricle and 
hinders the diastolic filling of the heart (Tyson et al. 1984), thereby leading to a decreased 
CO. Vasoconstriction is a general compensatory reaction in forms of shock involving low 
CO. It occurs as an appropriate response that serves to restore the declining arterial flow and 
pressure towards former values. The vasoconstriction is non-uniform, and the redistributed 
blood flow can maintain the blood supply for the heart and brain at a relatively normal level 
in the short run. The sympathetic vasoconstriction diverts the blood flow from organs with 
constricted arterioles to organs whose vessels constrict little under intense vasoconstriction. 
The resistance of the coronary circulation practically does not change, whereas the resistance 
of the skin, skeletal muscle and gastrointestinal circulations increases enormously (Bond and 
Green, 1983). This process is mediated through the activation of sympathetic nervous system 
and various humoral mediators (Kaszaki et al. 1989), leading to systemic vasoconstriction, 
tachycardia and fluid retention (Topalian et al. 2008). However, the price for the potentially 
beneficial effects of selective vasoconstriction is severe hypoxia in the underperfused organs 
(Bulkley et al. 1983, Bailey et al. 1987, Buerke et al. 2011). Moreover, the increased 
afterload may subsequently worsen the peripheral hypoperfusion and increase the oxygen 
demand of the myocardium. 
Circulatory disturbances of cardiac origin fundamentally influence the perfusion of 
other organs, and especially the gastrointestinal tract. Gastrointestinal perfusion is often 
compromised early relative to other vascular beds in critical illness, major surgery or exercise 
due to the neurohumoral elements of circulatory redistribution. This complex response is 
partly mediated through the sympathetic nervous system (Chien 1967), but various humoral 
mediators also participate in the maintenance of vasoconstriction (catecholamines, the renin-
angiotensin system and endothelins). 
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In cases of cardiac tamponade, drainage of the pericardial sac through 
pericardiocentesis or surgical pericardiotomy is the first choice for therapy (Seferovic et al. 
2006), but removal of the pericardial fluid can lead to a reperfusion phenomenon with further 
peripheral reactions. As a consequence of hypoxia and reoxygenation, reactive oxygen 
radicals are generated and polymorphonuclear neutrophil (PMN) leukocytes are activated. 
The formation of these radicals may lead to disintegration of the cell membranes, structural 
damage and decreased cellular functions (Boros et al. 1989, Prasad et al. 1990). High-
mobility group box protein-1 (HMGB1), released passively by necrotic and damaged cells, 
was recently identified as an important signal for leukocyte recruitment (Scaffidi et al. 2002). 
Further factors identified in the background of PMN leukocyte accumulation are an increased 
level of endothelin-1 (ET-1) formation and a decreased level of nitric oxide (NO) formation, 
which coexist in ischaemia-reperfusion syndromes (Boros 2003). ET-1, one of the most 
powerful endogenous vasoactive mediators, may contribute to the impairment of the 
microcirculation through its vasoconstrictor and pro-adhesive effects (Boros et al. 1998). 
Moreover, it results in histamine release from resident mast cells (Kaszaki et al. 2008), and 
influences the activation of the complement cascade (Soop et al. 2004). 
1.5. A possible therapeutic route: the complement system 
Complement was first discovered in the 1890s when it was found to aid or 
“complement” the killing of bacteria by heat-stable antibodies present in normal serum. The 
complement system consists of more than 30 proteins that are present either as soluble 
proteins in the blood or as membrane-associated proteins. This system is composed of a 
network of proteins that play an important role in innate and adaptive immunity, ranging from 
the opsonization of pathogens, through chemoattraction to the removal of apoptotic and 
necrotic cells. Activation of the system is exquisitely regulated, and inappropriate activation 
due either to deficiencies in key complement proteins or to dysregulated activation has 
adverse consequences (Sarma and Ward 2011). Complement activation leads to a sequential 
cascade of enzymatic reactions (known as complement activation pathways), resulting in the 
formation of the potent anaphylatoxins C3a and C5a, which elicit a plethora of physiological 
responses that range from chemoattraction to apoptosis. These proteins are capable of cell 
lysis and the principal site of synthesis is the liver. Complement activation is known to occur 
through three different pathways: alternative, classical and lectin (Figure 1), involving 
proteins that mostly exist as inactive zymogens, which are sequentially cleaved and activated. 
Activation of the classical complement pathway occurs via C1, C4 and C2, and activation of 
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an alternative complement pathway via factor D, C3 and factor B. Both pathways lead to the 
activation of C3. The protein fragment C3b, split form C3, is necessary for activation of the 
terminal complement components, C5-9. These form the membrane attack complex. When 
inserted into cell membranes, they cause osmotic lysis of the cell. C3a and C5a bind to 
receptors on mast cells and basophils, resulting in the release of histamine and other 
mediators of anaphylaxis. 
C5a is a potent chemoattractant for PMNs and monocyte-macrophages. C5a is a 74 
aminoacid peptide generated from C5 during complement activation. C5a acts efficiently as 
an anaphylatoxin, stimulating cells such as leukocytes and endothelial cells, and is also a 
potent chemotactic factor for PMNs and other inflammatory cells bearing the C5a receptor. 
C5a is therefore considered to be one of the most potent inflammatory mediators. 
Inflammatory cells respond to nanomolar concentrations of C5a with intracellular Ca2+ 
mobilization, stimulation of chemotaxis, aggregation, degranulation and the production of 
superoxide anions (Fujita et al. 2004). 
 
 
Figure 1: The three pathways of complement activation, collectively resulting in biologically 
active split products of C3 and C5 (abbreviations: LPS - lipopolysaccharide; MBL – 
mannose-binding lectin; MASP-2 - MBL-associated protein-2; MAC - membrane attack 
complex) (Ward PA: Sepsis, apoptosis and complement. Biochem Pharmacol 2008; 76: 1383-
1388). 
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2. MAIN GOALS 
With regard to this background, we hypothesized that acute failure of the myocardial pump 
function is accompanied by significant inflammatory activation, which can play an important 
role in the development of further clinical complications. 
Our primary aim was to investigate the immediate effects of a cardiac tamponade on 
the central and peripheral haemodynamics, with special emphasis on the intestinal circulation. 
To this end, we designed a clinically relevant, large animal model with which to determine 
the macro- and microcirculatory changes induced by experimental cardiac tamponade. With 
this model, we planned to characterize the major components of the pro-inflammatory profile 
of the post-tamponade phase, in association with the changes in overall haemodynamics. We 
assumed that a better understanding of the elements of this mechanism may lead to new 
prospects for interventions designed to dampen or reverse the secondary, detrimental 
consequences of acute heart failure. 
Our secondary aim was to investigate the inhibitory effects of the complement C5a 
antagonist acetyl-peptide-A (AcPepA), a synthetic, antisense, 17 amino acid peptide 
acetylated at the N-terminal alanine, on the early circulatory and inflammatory changes in our 
animal model of cardiac tamponade. It is widely accepted that inflammatory activation plays a 
decisive role in these conditions, although the potential of ‘anti-inflammatory’ compounds to 
prevent or cure low perfusion-induced in vivo processes is very limited. With this 
background, we hypothesized that the early inhibition of C5a might well reduce the adverse 
haemodynamic and inflammatory consequences after the relief of the cardiac tamponade. 
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3. MATERIALS AND METHODS 
The experiments were carried out in strict adherence to the NIH guidelines for the use 
of experimental animals and the study was approved by the Ethical Committee for the 
Protection of Animals in Scientific Research at the University of Szeged (V./148/2013). 
3.1. Instrumentation of animals in Studies I and II 
Inbred Vietnamese minipigs of both sexes (weighing 24±3 kg) were fasted for 12 h 
preoperatively, but received water ad libitum. Anaesthesia was induced with a mixture of 
ketamine (20 mg kg-1) and xylazine (2 mg kg-1 im) and maintained with a continuous infusion 
of propofol (50 µL min-1 kg-1 iv; 6 mg kg-1 h-1) supplemented with ketamine (5 mg kg-1) - 
xylazine (0.5 mg kg-1) mixture im before thoracotomy and after 90 min of the observation 
period. After endotracheal intubation, the animals were mechanically ventilated with the tidal 
volume set at 9±2 mL kg-1, and the respiratory rate was adjusted to maintain the end-tidal 
pressure of CO2 and arterial pCO2 in the range 35-45 mmHg. Positive end-expiratory pressure 
was not applied during the cardiac tamponade. 
The animals were placed in a supine position on a heating pad for maintenance of the 
body temperature between 36 and 37 oC, and received an infusion of Ringer's lactate at a rate 
of 10 mL kg-1 h-1 during the experiments. The right jugular vein was cannulated (7 F; 
Edwards Lifesciences LLC, Irvine, U.S.A.) for the measurement of central venous pressure 
(CVP) and for fluid administration. The right femoral artery and vein were dissected and a 
thermodilution catheter (PULSION Medical Systems SE, Munich, Germany) was placed in 
the femoral artery for the measurement of mean arterial pressure (MAP) and CO by a 
transpulmonary thermodilution method (PiCCO; PULSION Medical Systems SE, Munich, 
Germany). A pulmonary artery catheter (PV2057 VoLEF Catheter; PULSION Medical 
Systems SE, Munich, Germany) was inserted via the right femoral vein into the pulmonary 
artery by tracing the pressure signals. 
After a midline abdominal incision, the root of the superior mesenteric artery (SMA) 
was dissected free. An ultrasonic flow probe (Transonic Systems Inc., Ithaca, NY, U.S.A.) 
was placed around the exposed SMA to measure the mesenteric blood flow. 
Left lateral thoracotomy was performed and a cannula was fixed into the pericardial 
cavity in all groups. In all protocols, the animals were monitored continuously and a period of 
30 min was allowed for recovery from surgery. At the end of the experiments, small intestinal 
tissue biopsies were taken for biochemical and immunohistochemical analysis and the 
animals were killed with an overdose of sodium pentobarbital. 
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3.2. Haemodynamic measurements in Studies I and II 
CVP and blood flow signals were monitored continuously and registered with a 
computerized data-acquisition system (SPELL Haemosys; Experimetria Ltd., Budapest, 
Hungary). For further haemodynamic monitoring, we used a combination of PiCCO Plus V 
5.2.2 and VoLEF V 1.0 (PULSION Medical Systems SE, Munich, Germany) monitors (Végh 
et al. 2009). The MAP, CO, HR, GEDV and extravascular lung water index (EVLWI) were 
measured with the PICCO Plus monitoring system, while the PiCCO–VoLEF monitor system 
was applied to measure the pulmonary arterial pressure (PAP), and calculate RHEDV and 
LHEDV, systemic vascular resistance index (SVRI) and pulmonary vascular resistance index 
(PVRI). All haemodynamic parameters were indexed for body surface area or body weight. 
These techniques were previously used and validated in an accompanying study (Molnár et al. 
2011). A detailed description of the transpulmonary thermodilution and volumetric analysis is 
provided elsewhere (Phillips et al. 2009). 
3.3. Evaluation of intestinal microcirculation: pCO2 gap measurements 
A difference between local tissue and arterial pCO2 (paCO2) levels is a sensitive 
parameter with which to evaluate the effectiveness of therapy aimed at counteracting a 
microcirculatory dysfunction in the gastrointestinal tract (Kolkman et al. 2000). A silastic 
balloon-free tonometric probe (Tonosoft Medical Technical and R&D Ltd., Hungary) was 
introduced through a small enterotomy into the intestinal lumen (Boda et al. 2006) to monitor 
intramucosal pCO2 levels by capnometry. For calculation of the pCO2 gap values, 
simultaneously taken paCO2 levels were subtracted from the tonometric pCO2 levels. Arterial 
and venous blood samples were taken at the baseline and after every hour, and blood-gas 
parameters were measured with a blood-gas analyser (Cobas b121, Roche, Austria). 
3.4. Biochemical measurements 
Five-mL blood samples were drawn from the jugular vein into chilled polypropylene 
tubes containing EDTA (1 mg mL-1) as the scheduled experimental protocol. The blood 
samples were centrifuged at 1200g for 10 min at 4 oC. The plasma samples were next 
collected and stored at -70 oC until assay. 
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Big-endothelin measurements in plasma 
Blood samples were collected into chilled polypropylene tubes containing EDTA. 
Plasma levels of big-ET, a 38 amino acid stable precursor protein of ET-1, were measured 
with a commercially available kit (Biochemica Hungaria Kft., Budapest, Hungary). 
Tumour necrosis factor-alfa measurements in plasma 
The plasma concentration of tumour necrosis factor-alfa (TNF-α) was measured with a 
commercially available porcine ELISA kit (Biochemica Hungaria Kft., Budapest, Hungary). 
High-mobility group box protein-1 measurements in plasma 
The plasma concentration of HMGB-1 was measured with a commercially available 
HMGB-1 ELISA kit (Shino-Test Corporation, Kanagawa, Japan). 
Histamine measurements in plasma 
Plasma histamine concentrations were determined by a commercially available 
enzyme-linked immunoassay (Quantikine ultrasensitive EIA kit for histamine; Biomedica 
Hungaria Kft, Budapest, Hungary). 
Plasma nitrite/nitrate level measurements 
The levels of plasma nitrite/nitrate (NOx), stable end-products of NO, were measured 
by means of the Griess reaction. The assay depends on the enzymatic reduction of nitrate to 
nitrite, which is then converted into a coloured azo compound detected spectrophotometrically 
at 540 nm (Moshage et al. 1995). 
Measurement of whole-blood superoxide production 
For the whole-blood superoxide production measurements, the chemiluminometric 
method of Zimmermann et al. was used (Zimmermann et al. 1991). During the 
measurements, 10 µL of whole blood was added to 1 mL of Hanks solution and the mixture 
was kept at 37 oC until assay. The chemiluminometric response was measured with a Lumat 
LB9507 luminometer (Berthold, Vienna, Austria) during 30 min after the addition of 100 µL 
of lucigenin. 
Plasma troponin-T level measurements 
Cardiac troponin-T levels in plasma samples were measured by highly sensitive 
electrochemiluminescent immunoassay (ECLIA; Elecsys 2010, Roche Diagnostics GmbH, 
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Mannheim, Germany). The analytical sensitivity was 5 ng L-1, and the intra- and interassay 
variations in the measured concentration range were 3.2 and 6.2 CV%, respectively. 
Myeloperoxidase activity measurement 
The activity of myeloperoxidase (MPO), as a marker of tissue PMN leukocyte 
infiltration, was measured via intestinal biopsies (Kuebler et al. 1996). Briefly, the sample 
was homogenized with Tris-HCl buffer (0.1 M, pH 7.4) containing 0.1 mM 
phenylmethylsulfonyl fluoride to block tissue proteases, and then centrifuged at 4 oC for 20 
min at 2000g. The MPO activities of the samples were measured at 450 nm (UV-1601 
spectrophotometer, Shimadzu, Japan) and the data were referred to the protein content. 
Immunohistochemistry 
The presence of a complement C3 deposit in the small intestinal mucosa was detected 
by immunohistochemistry (IHC) (Girardi et al. 2003) on formalin-fixed, paraffin-embedded 
small intestinal sections, using rabbit polyclonal anti-complement fragment C3c primary 
antibody (Bioss Inc, Woburn, MA, USA). The sections were deparaffinized for 5 min, which 
was followed by antigen retrieval with citrate buffer for 20 min. The activity of endogenous 
peroxidases was blocked with 5% H2O2 for 10 min. The non-specific interactions were 
inhibited during the next 30 min of incubation. The primary antibody was diluted 1:500 in 
antibody diluent for IHC (BD Pharmingen, San Diego, CA, USA). After washing of the 
sections, the secondary antibody was diluted 1:500 and the samples were incubated for 8 min. 
Sections were counterstained with 3,3'-diaminobenzidine and haematoxylin. The entire IHC 
investigation was carried out with an automatic Leica Bond-max IHC instrument (Leica 
Microsystems, Tokyo, Japan). For quantitative analysis, immunostained sections were 
examined under a light microscope. The coded sections were analysed by an independent 
histopathology specialist. The numbers of capillaries positive for complement fragment C3c 
were assessed at a magnification of 400x. 
3.5. Experimental protocols 
In Study I, the animals were randomly divided into two experimental groups. Group 1 
(n=7) served as sham-operated control, with the same time-frame and sampling as in group 2. 
A pericardial tamponade (group 2; n=8) was induced for 60 min by the intrapericardial 
administration of colloid solution (60-90 mL hydroxyethyl starch 6%; Fresenius Kabi 
Deutschland GmbH, Homburg, Germany), while the MAP was kept in the interval 40-45 
 20 
mmHg. After this period, the fluid was removed from the pericardial sac and the animals were 
monitored for 180 min post-tamponade. 
Peripheral blood samples were taken at baseline, and then after 75 min, after 150 min 
and at the end of the observation period (240 min) to detect the levels of vasoactive and 
inflammatory mediators (big-ET, histamine, NOx, troponin-T, HMGB-1 and whole-blood 
superoxide production). Small intestinal tissue biopsies were taken at the end of the 
experiments for MPO activity measurements and IHC analysis of the complement C3 deposit. 
In Study II, the animals were randomly allocated into one or other of three 
experimental groups with the same time-frame and sampling as in Study I. Group 1 (n=6) 
served as sham-operated control, while in groups 2 (n=7) and 3 (n=6) cardiac tamponade was 
induced. Group 3 was treated with C5a antagonist AcPepA (a single administration of 4 mg 
kg-1 in 5 mL saline iv into the jugular vein in a 5-min infusion) after 45 min of cardiac 
tamponade. AcPepA (ASGAPAPGPAGPLRPMF) containing an acetylated N-terminal 
alanine was synthetized and purified (> 95% purity) by Biologica Co. Ltd. (Nagoya, Japan). 
The peptide was dissolved in saline and used in a concentration of 2 mg mL-1 as reported 
previously (Okada et al. 2011). Vehicle (saline) administration was applied in groups 1 and 2 
by the same protocol. The beginning of tamponade is denoted as 0 min. Blood and tissue 
sampling were performed during the 240 min observation period as described in Study I. 
3.6. Statistical analysis 
Data analysis was performed with a statistical software package (SigmaStat for 
Windows, Jandel Scientific, Erkrath, Germany). The distribution of our experimental data 
was analysed by the Kolmogorov-Smirnov normality test. Failure of the normality test 
indicated non-parametric distribution of the data. In Studies I-II, non-parametric methods 
were used. Friedman repeated measures analysis of variance on ranks was applied within the 
groups. Time-dependent differences from the baseline (time 0) for each group were assessed 
by Dunn's method, and differences between groups were analysed with the Mann-Whitney 
test (in Study I) or with Kruskal-Wallis one-way analysis of variance on ranks, followed by 
Dunn's method for pairwise multiple comparison (in Study II). In the Figures and Tables, 
median values and the 25th (lower whisker) and 75th (upper whisker) percentiles are given. 
*p<0.05 within groups vs baseline values, Xp<0.05 between groups vs sham-operated group 
values, #p<0.05 between AcPepA-treated group vs cardiac tamponade group. 
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4. RESULTS 
4.1. Study I – Haemodynamic and inflammatory responses after cardiac tamponade 
4.1.1. Changes in haemodynamics 
In the sham-operated group, there were no significant haemodynamic changes as 
compared with the baseline values, and the mediator levels did not change significantly 
during the observation period. 
The MAP was maintained in the interval 40-45 mmHg during the tamponade for 60 
min (Figure 2A) by the infusion of colloid fluid into the pericardial sac, which resulted in a 
significant, approximately 60% decline in CO in the group undergoing cardiac tamponade. 
The SVRI and HR were increased significantly (by 32% and 66%, respectively; Table 1). 
After relief of the tamponade, the MAP was significantly lower in the cardiac tamponade 
group as compared with the control group, while the CO and HR returned to the baseline 
despite the reduced MAP. 
 
Table 1. Effects of cardiac tamponade on the CO, HR and SVRI. Values are medians (25th 
percentile; 75th percentile). * p<0.05 within group; X p<0.05 between groups vs control 
group; 
 -5 min 30 min 60 min 90 min 120 min 180 min 240 min 
CO [L min-1 m-2] 
Sham-
operated 
2.60 
(2.39; 2.97) 
2.73 
(2.25; 3.34) 
2.74 
(2.30; 3.14) 
2.85 
(2.60; 3.28) 
2.94 
(2.65; 3.30) 
2.85 
(2.51; 3.35) 
2.82 
(2.62; 3.33) 
Cardiac 
tamponade 
2.82 
(2.46; 3.01) 
1.36 * X 
(0.95; 1.89) 
1.19 * X 
(1.03; 1.30) 
2.44 
(2.29; 3.01) 
2.48 
(2.16; 3.03) 
2.40 
(2.13; 2.74) 
2.40 
(2.07; 2.79) 
HR [beat min-1] 
Sham-
operated 
124 
(120; 137) 
128 
(118; 134) 
125 
(119; 134) 
126 
(115; 137) 
127 
(104; 135) 
120 
(104; 128) 
122 
(106; 126) 
Cardiac 
tamponade  
113 
(103; 118) 
175 * X 
(136; 203) 
188 * X 
(173; 206) 
125 
(122; 143) 
118 
(113; 120) 
114 
(105; 116) 
113 
(98; 122) 
SVRI [mmHg mL-1 min-1 kg-1] 
Sham-
operated 
0.79 
(0.73; 0.83) 
0.81 
(0.75; 0.85) 
0.74 
(0.69; 0.79) 
0.68 
(0.66; 0.77) 
0.64 
(0.58; 0.68) 
0.66 
(0.57; 0.71) 
0.67 
(0.61; 0.75) 
Cardiac 
tamponade 
0.78 
(0.71; 0.92) 
0.91 
(0.80; 0.94) 
1.03 * 
(0.84; 1.06) 
0.83 
(0.72; 0.85) 
0.83 X 
(0.69; 0.93) 
0.82 X 
(0.73; 0.91) 
0.79 
(0.71; 0.91) 
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Figure 2. Changes in mean arterial pressure (A) and central venous pressure (B) in the sham-
operated (triangles with thin continuous line) and cardiac tamponade (squares with thick solid 
line) groups. The box indicates the duration of the cardiac tamponade. 
The decline in the venous return during the tamponade was evidenced by the increased 
CVP (Figure 2B). This process was accompanied by decreases in RHEDV and LHEDV 
(Figure 3AB). After relief of the tamponade, the CVP and RHEDV normalized, but the 
LHEDV did not reach the baseline value in the tamponade group; it remained significantly 
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lower as compared with the sham-operated group (Figures 3AB). These changes demonstrate 
the long-lasting impairment of the LV function following the cardiac tamponade. 
 
Figure 3. Changes in right heart end-diastolic volume (A) and left heart end-diastolic volume 
(B) in the sham-operated (triangles with thin continuous line) and cardiac tamponade (squares 
with thick solid line) groups. The box indicates the duration of the cardiac tamponade.  
The cardiac tamponade resulted in a significant, transient decrease in PAP and a 2-fold 
elevation of the PVRI (Table 2). In the post-tamponade period, further long-lasting significant 
increases in PVRI and PAP occurred as compared with the sham-operated group, while the 
EVLWI was significantly elevated at the end of the observation period (Table 2). 
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Table 2. Effects of cardiac tamponade on PAP, PVRI and EVLWI. Values are medians (25th 
percentile; 75th percentile). * p<0.05 within group; X p<0.05 between groups vs control 
group;  
 -5 min 30 min 60 min 90 min 120 min 180 min 240 min 
PAP [mmHg] 
Sham-
operated 
30.6 
(27.0; 35.0) 
31.1 
(27.3; 35.4) 
28.9 
(27.5; 35.6) 
31.2 
(26.0; 36.0) 
30.3 
(27.4; 34.8) 
30.3 
(26.8; 32.5) 
30.8 
(28.3; 33.6) 
Cardiac 
tamponade 
30.4 
(27.3; 34.2) 
24.3 * X  
(21.1; 27.8) 
30.0 
(19.2; 35.6) 
38.4 
(30.0; 41.3) 
36.5 
(34.4; 42.7)  
41.2 * X  
(35.3; 43.2) 
37.9 
(31.9; 42.8) 
PVRI [mmHg mL-1 min-1 kg-1] 
Sham-
operated 
0.37 
(0.31; 0.39) 
0.35 
(0.30; 0.43) 
0.31 
(0.29; 0.35) 
0.29 
(0.25; 0.35) 
0.29 
(0.25; 0.32) 
0.32 
(0.24; 0.36) 
0.31 
(0.23; 0.38) 
Cardiac 
tamponade  
0.41 
(0.26; 0.50) 
0.75 * X  
(0.66; 0.98) 
0.88 * X  
(0.81; 0.95) 
0.48 X  
(0.42; 0.53) 
0.51 X  
(0.44; 0.63) 
0.54 X  
(0.49; 0.60) 
0.49 X  
(0.47; 0.54) 
EWLV [mL kg-1] 
Sham-
operated 
8.0 
(7.8; 9.0) 
8.2 
(8.0; 9.0) 
8.5 
(8.0; 9.0) 
8.5 
(8.0; 9.1) 
8.5 
(8.0; 9.1) 
8.4 
(8.0; 9.0) 
8.4 
(8.0; 9.0) 
Cardiac 
tamponade 
8.0 
(8.0; 9.0) 
8.0 
(7.5; 8.8) 
8.0 
(7.3; 8.9) 
8.5 
(8.0; 10.8) 
9.0 
(8.3; 10.8) 
9.5 * 
(8.5; 10.0) 
10.0 * X  
(9.0; 11.0) 
 
The significant decrease in SMA blood flow during the tamponade indicated a 
deteriorated mesenteric circulation. After the removal of the pericardiac fluid, the SMA flow 
returned to the control values (Figure 4A). 
The pCO2 gap, the difference between the local tissue and the arterial pCO2, is a 
reliable index of local tissue perfusion. The pCO2 gap increased significantly during the 
tamponade, while relief of the tamponade resulted in a significantly lower gap, though the 
values remained significantly higher than that for the sham-operated control group throughout 
the post-tamponade period (Figure 4B). 
 25 
 
Figure 4. Changes in superior mesenteric artery (SMA) blood flow (A) and intestinal pCO2 
gap (B) in the sham-operated (triangles with thin continuous line) and cardiac tamponade 
(squares with thick solid line) groups. The box indicates the duration of the cardiac 
tamponade. 
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4.1.2. Changes in biochemical parameters 
In the cardiac tamponade group, increased superoxide radical production was observed 
at the beginning of the post-tamponade phase (Figure 5). In parallel, the plasma histamine 
levels were increased significantly by 75 and 240 min of the observation period: M=16.2 nM 
(p25=15.5; p75=16.6) and M=10.3 nM (p25=9.1; p75=12.8), respectively, vs the baseline 
(M=7.5; p25=6.4; p75=8.8), or vs the corresponding value for the sham-operated group 
(M=7.4 nM; p25=5.7; p75=9.4). 
 
Figure 5. Changes in whole-blood superoxide production in the sham-operated (triangles with 
thin continuous line) and cardiac tamponade (squares with thick solid line) groups. The box 
indicates the duration of the cardiac tamponade. 
The NOx concentration in the plasma allows an estimate of the changes in NO 
production. The consequence of the cardiac tamponade in this respect was a slight, but 
statistically significant increase in NOx level at the end of the post-tamponade period as 
compared with the baseline level and with that for the sham-operated group (data not shown). 
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Figure 6. Changes in plasma big-endothelin (ET) concentration (A) and high-mobility group 
box protein-1 (HMGB-1) level (B) in the sham-operated (triangles with thin continuous line) 
and cardiac tamponade (squares with thick solid line) groups. The box indicates the duration 
of the cardiac tamponade.  
Big-ET is a stable precursor of ET-1 with a longer half-life. The plasma big-ET level 
increased significantly (4-5-fold) in response to the cardiac tamponade (Figure 6A). 
HMGB-1 is an effective signal for leukocyte activation, which causes an escalation of 
the inflammatory process. The plasma level of HMGB-1 was elevated significantly after the 
compression of the heart (Figure 6B). 
 28 
The rate of PMN leukocyte accumulation was determined through measurement of the 
MPO activity of the intestinal tissue samples taken at the end of the experiments. The level of 
MPO activity was significantly higher in the small intestinal tissue samples of the cardiac 
tamponade group, indicating the increased accumulation of PMN leukocytes (cardiac 
tamponade: M=5.37 (p25=4.8; p75=6.22; U mg protein-1) vs sham-operated: M=2.84 
(p25=2.19; p75=3.22). 
The troponin-T level in the plasma allows an estimate of the cardiomyocyte damage. 
The mean concentrations of troponin-T were significantly increased after the compression of 
the heart and at the end of the post-tamponade period as compared with the baseline and with 
those for the sham-operated group (Figure 7). 
 
Figure 7. Changes in plasma troponin-T level in the sham-operated (triangles with 
thin continuous line) and cardiac tamponade (squares with thick solid line) groups. The box 
indicates the duration of the cardiac tamponade. 
Activation of the complement cascade was evaluated by the presence of a complement 
C3 deposit in the small intestinal mucosa with the IHC method (Figure 8). In each field of 
view of the slides, the number of capillaries showing C3 deposit positivity was counted. The 
number of C3 deposits was significantly higher in the tamponade group than in the sham-
operated group (M=3; p25=1; p75=4.5 vs M=0; p25=0; p75=1 deposits/field of view). 
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Figure 8. Changes in complement C3 deposition as demonstrated by IHC analyses in the 
small intestinal mucosal biopsies taken at the end of the experiments: H&E staining in the 
sham-operated (A) and cardiac tamponade (C) groups; extensive C3 deposition with IHC 
staining in the cardiac tamponade (D) group as compared with the sham-operated (B) group.  
 
4.2. Study II – Cardiac effects of complement C5a antagonist treatment 
4.2.1. Changes in cardiac and pulmonary haemodynamics 
In the sham-operated group, there were no significant haemodynamic changes as 
compared with the baseline values, and the mediator levels did not change significantly 
during the observation period. 
MAP was kept in the interval 40-45 mmHg during cardiac tamponade for 60 min 
(Figure 9A) by the infusion of colloid fluid into the pericardial sac, and this resulted in a 
significant 65% decline in CO in both groups undergoing cardiac tamponade (Figure 9B) and 
a significant increase in HR (Figure 10B). After relief of the tamponade, the MAP was 
significantly lower in the non-treated cardiac tamponade group as compared with the control 
group, while the CO and HR returned to the baseline values despite the reduced MAP. 
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Administration of AcPepA after 45 min of the cardiac tamponade resulted in an elevation of 
the MAP, did not influence the CO, and caused a significant decrease in the HR as compared 
with the untreated cardiac tamponade group in the post-tamponade period (Figures 9A-B and 
10B). 
 
Figure 9. Changes in mean arterial pressure (A) and cardiac output (B) in the sham-operated 
(solid triangles with continuous line), cardiac tamponade (empty squares with solid line) and 
AcPepA-treated (empty circles with solid line) groups. The box indicates the duration of the 
cardiac tamponade, and the arrow indicates the time of treatment with AcPepA. 
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The decline in the venous return during the tamponade was evidenced by the increased 
CVP (Figure 2B). This process was accompanied by a decrease in GEDV (Figure 10A). The 
GEDV did not reach the baseline values in the non-treated cardiac tamponade group (Figure 
10A) after relief of the tamponade. These changes demonstrate the long-lasting impairment of 
the venous return flow following the cardiac tamponade. After AcPepA administration, we 
observed significant increases in the preload parameters in the post-tamponade period: the 
CVP was set to a significantly higher level (Annex II, Figure 2A) and the GEDV 
demonstrated the increased returning blood flow (Figure 10A). 
 
Figure 10. Changes in global end-diastolic volume (A) and heart rate (B) in the sham-
operated (solid triangles with continuous line), cardiac tamponade (empty squares with solid 
line) and AcPepA-treated (empty circles with solid line) groups. The box indicates the 
duration of the cardiac tamponade, and the arrow indicates the time of treatment with 
AcPepA. 
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The cardiac tamponade caused a permanent impairment of the LV function, as 
demonstrated by the long-lasting decrease in LHEDV (Figure 11). Administration of AcPepA 
after 45 min of the cardiac tamponade normalized the LHEDV as compared with the 
untreated cardiac tamponade group in the post-tamponade period. In contrast with the 
LHEDV, the RHEDV returned to the baseline level after the relief of the tamponade (Figure 
3B) and it was not influenced by complement C5a antagonist treatment (data not shown). 
 
Figure 11. Changes in left heart end-diastolic volume in the sham-operated (solid triangles 
with continuous line), cardiac tamponade (empty squares with solid line) and AcPepA-treated 
(empty circles with solid line) groups. The box indicates the duration of the cardiac 
tamponade, and the arrow indicates the time of treatment with AcPepA. 
The cardiac tamponade caused significant changes in the pulmonary circulation in 
both the tamponade and the post-tamponade periods (Table 2). AcPepA treatment decreased 
the long-lasting elevations in PAP and PVRI that occurred after the relief of the tamponade as 
compared with the untreated cardiac tamponade group (Figure 12A,B). However, the 
elevation caused in EVLWI by the cardiac tamponade was not influenced significantly by this 
treatment at the end of the observation period (data not shown). 
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Figure 12. Changes in pulmonary arterial pressure (A) and pulmonary vascular resistance (B) 
in the sham-operated (solid triangles with continuous line), cardiac tamponade (empty squares 
with solid line) and AcPepA-treated (empty circles with solid line) groups. The box indicates 
the duration of the cardiac tamponade, and the arrow indicates the time of treatment with 
AcPepA. 
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4.2.2. Changes in biochemical parameters 
Change in the TNF-α level is a sensitive and early signal indicative of the 
inflammatory process. In our pig model, a 10-fold elevation in the plasma level of TNF-α was 
detected after the compression of the heart; the level then decreased successively until the end 
of the observation period (Figure 13A).  
 
Figure 13. Changes in plasma TNF-α (A) and histamine (B) levels in the sham-operated 
(solid triangles with continuous line), cardiac tamponade (empty squares with solid line) and 
AcPepA-treated (empty circles with solid line) groups. The box indicates the duration of the 
cardiac tamponade, and the arrow indicates the time of treatment with AcPepA. 
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The increased level of histamine release in the plasma suggests the activation of the 
hypoxia-sensitive inflammatory cells (mast cells and basophil leukocytes). As a result of the 
cardiac tamponade, the histamine level increased significantly by 15 min of the post-
tamponade phase (Figure 13B).  
After AcPepA administration, the characteristic biochemical changes following the 
cardiac tamponade were significantly different. The AcPepA treatment reduced the 
concentrations of TNF-α and histamine in the plasma after the compression of the heart and in 
the post-tamponade period as compared with the sham-operated group (Figure 13A,B). 
A measurable troponin-T level in the plasma allows an estimate of the ischaemic 
effect of cardiac tamponade. The cardiac tamponade caused a significant elevation in the 
mean concentration of troponin-T after the relief of the tamponade and at the end of the post-
tamponade period, while the administration of AcPepA resulted in a lower level of troponin-T 
in the plasma in the post-tamponade phase (Figure 14). 
 
Figure 14. Changes in plasma troponin-T level in the sham-operated (solid triangles with 
continuous line), cardiac tamponade (empty squares with solid line) and AcPepA-treated 
(empty circles with solid line) groups. The box indicates the duration of the cardiac 
tamponade, and the arrow indicates the time of treatment with AcPepA. 
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Activation of the complement cascade was detected via the increased presence of a 
complement C3 deposit in the tamponade group as compared with the sham-operated group in 
the small intestinal mucosa with the IHC method. However, the number of capillaries 
displaying C3 deposit positivity was lower in the AcPepA-treated tamponade group than in 
the non-AcPepA-treated group (Figure 15). 
 
Figure 15. Changes in complement C3 deposition demonstrated by immunohistochemical 
analyses in the small intestinal mucosal biopsies taken at the end of the experiments.  
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5. DISCUSSION 
5.1. Study I 
Pericardial tamponade is accompanied by high mortality and postoperative 
complication rates, even in the event of adequate treatment. In cases of blunt chest trauma, the 
mortality may exceed 80% (Brathwaite et al. 1990), while a 22% mortality rate was reported 
after elective open-heart surgery in clinically proven cases of localized cardiac tamponade 
(Grumann et al. 2012). Our primary goal was to characterize the haemodynamic effects of 
temporary mechanical compression of the heart and to outline a multi-faceted inflammatory 
process which may cause potential risks in the post-tamponade phase. This is required to 
identify the inflammatory mediators, with a potential role in this inflammatory cascade 
system. 
The major finding of Study I is that the post-tamponade period is characterized by a 
decreased level of systemic perfusion and by an impaired LV function and pulmonary 
circulation, as evidenced by the MAP, LHEDV, PAP, PVRI and EVLWI data. The pCO2 gap 
changes suggested that, in parallel, a significant intestinal microcirculatory dysfunction 
evolved in this porcine model. More importantly, these responses were associated with abrupt 
increases in the level of superoxide radical production, big-ET, troponin-T, HMGB1, 
histamine, intestinal MPO activity and complement activation during the post-tamponade 
phase. 
The cardiac filling disorder induced different vasoconstrictive compensatory reactions 
in the systemic and pulmonary circulations: the increase in PVRI (112%) was much higher 
than that in SVRI (32%). Previous experimental and clinical data suggest that the increasing 
pericardial pressure causes a continuous decline in coronary blood flow due to an increase in 
coronary vascular resistance (Klopfenstein et al. 1987, Skalidis et al. 2000). Skalidis et al. 
observed a decreased hyperaemic flow under increased pericardial pressure, which implies an 
augmented susceptibility to myocardial ischaemia (Skalidis et al. 2000). The significantly 
increased HR during the acute phase of the tamponade could also contribute to the cardiac 
hypoxia. The decreased CO is compensated by the increased HR, though the length of the 
systole does not change, while the diastole is shortened. Such a high frequency then results in 
less time for oxygen delivery to the cardiac muscle cells, and the degree of oxygenation of the 
heart is therefore worsened. The significantly elevated level of troponin-T during the acute 
phase of the tamponade also demonstrates the deterioration of oxygenation and damage of the 
cardiac muscle cells. 
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After the relief of the tamponade, the MAP was decreased, while the CO was kept 
compensated, and there were no significant differences as compared with the control group. 
This may be explained by the normalized preload, as evidenced by the normalized CVP and 
RHEDV, and the moderate elevation of the afterload. However, the significant decrease in 
LHEDV indicates a LV dysfunction during the post-tamponade phase. The persistent 
elevations in PAP and PVRI could contribute to this process, together with the lung oedema, 
as revealed by the elevated EVLWI. These conclusions are supported by clinical observations 
on early cardiac failure and pulmonary oedema after removal of the pericardial effusion 
(Ligero et al. 2006, Bernal et al. 2007). 
In this clinically relevant large animal model, the pericardial tamponade triggered 
characteristic macro- and microcirculatory changes in the intestines. While the SMA flow, 
which reflects the blood supply of the small intestine and colon, was diminished during the 
tamponade, a prolonged impairment of the mucosal microcirculation was detected. This is in 
accordance with previous assumptions that the macro- and microhaemodynamics may change 
relatively independently, or may be dissociated in stress conditions (De Backer et al. 2010). 
In the background of these haemodynamic alterations, a multi-faceted role of humoral 
mediators, including ET-1, is proposed. Hypoxia is considered to be one of the basic stimuli 
for ET-1 synthesis. This peptide is produced predominantly by the endothelium, but in 
pathophysiological states other cell types, such as leukocytes, macrophages, smooth muscle 
cells, cardiomyocytes and mesangial cells, can also serve as sources of its release (Boros 
2003). The increased plasma level of ET-1 could be responsible for the decreased coronary 
perfusion (Fazekas et al. 2001) and pulmonary hypertension. The activation of 
vasoconstrictor ET receptors can further play a decisive role in acute microcirculatory 
disorders of the peripheral cardiovascular system. It has been shown that selective ET-A 
receptor antagonism increases the CO, decreases the peripheral resistance (Wolfard et al. 
1999, Kaszaki et al. 2008) and reduces intestinal microvascular injury and PMN leukocyte 
accumulation during ischaemia-reperfusion (Wolfard et al. 2002). 
In addition to its independent role as a dominant vasoconstrictor, the peptide may also 
influence the functions of other cell types in the circulatory system. ET-1 has been reported to 
induce leukocyte rolling and adherence through a predominantly ET-A receptor-mediated 
mechanism (Boros et al. 1998). There is a close relationship between a compromised mucosal 
blood flow and the magnitude of PMN leukocyte-endothelial cell interactions in the intestines 
(Wolfard et al. 2002). On the other hand, ET-1 also causes histamine release from mast cells, 
which may lead to enhanced vascular permeability and a relative blood loss into the dilated 
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vessels (Kaszaki et al. 2008). Histamine release in the pulmonary circulation contributes to 
the increase in EVLWI (Walkenstein et al. 1985), while in the splanchnic area, histamine 
release probably plays a role in the counter-regulation of the excessive, prolonged 
vasoconstriction that contributes to the lethal outcome (Kaszaki et al. 1989). Furthermore, 
ET-1 activates NADPH oxidase, resulting in an increased superoxide radical production 
(Loomis et al. 2005), which can simultaneously reduce NO production, leading to the 
formation of the highly cytotoxic peroxynitrite (Sheehy et al. 1998). From this point of view, 
the excessive release of ET-1 can be the key player as concerns the spreading inflammatory 
responses, when intensive complement activation is also ignited. The presence of complement 
C3 deposits was verified in this tamponade model and we found increased plasma levels of 
HMGB-1 too, the release of which is additionally directly mediated by the complement 
cascade. In this scenario, HMGB1 release is a further danger signal to responsive cells, which 
amplifies the production and secretion of other pro-inflammatory mediators and finally 
induces excessive inflammation (Yang et al. 2002, Ulloa and Messmer 2006). 
This study has some limitations. On the one hand, thoracotomy causes severe surgical 
trauma. A diaphragmatic window through laparotomy could be a possible alternative to reach 
the pericardial cavity (Park et al. 2008). Nevertheless, safe catheterization of the pericardial 
sac, and quick guidance of the diagnostic instrumentation into the correct positions in the 
heart cavities are advantages of the open chest model. On the other hand, the inflammatory 
reaction may be non-specific because cardiogenic and hypovolaemic shock components are 
not mutually exclusive. Decreases in MAP and CO, splanchnic perfusion and 
microcirculatory damage may be observed in nearly all forms of circulatory shock (e.g. 
hypovolaemic, cardiogenic or distributive). Nevertheless, there are also tamponade-specific 
consequences, such as an elevation of the CVP, a decrease in LHEDV and an increased 
plasma troponin-T level, which may be direct signs and consequences of tamponade-induced 
cardiac ischaemia. 
In conclusion, we have demonstrated characteristic macrohaemodynamic changes, 
together with apparent signs of a damaged LV function and a splanchnic inflammatory 
reaction after the relief of a tamponade. The evidence further suggests that numerous 
biomarkers, including superoxide radicals, big-ET, HMGB1, histamine, MPO activity or 
components of the complement system, are significant factors of the inflammatory cascade in 
this porcine model of pericardial tamponade. On the basis of these results, we assume that 
these mediators could be promising targets for therapeutic intervention in the future. 
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5.2. Study II 
It is widely accepted that inflammatory activation plays a decisive role in low-flow 
conditions, although the potential of ‘anti-inflammatory’ compounds to prevent or cure low 
perfusion-induced in vivo processes is very limited. With this objective, Study II was 
designed to develop adjuvant therapy which is able to improve the early haemodynamic and 
inflammatory changes that occur after restoration of the cardiac tamponade. Numerous 
experimental results (Ward 2008; Sarma and Ward 2011), together with our findings from 
Study I, suggested that the components of the complement system could be promising targets 
for therapeutic intervention. For this purpose, we planned to use the early inhibition of 
complement C5a with AcPepA, a synthetic, antisense, 17-amino acid peptide acetylated at the 
N-terminal alanine (Okada et al. 2007), during the acute phase of cardiac tamponade. It has 
been shown that this compound is capable of binding directly to C5a (in its 37-53 amino acid 
region) in a concentration-dependent manner. The binding between the molecules is very 
strong (the dissociation requires treatment with 6 M urea in vitro) (Fujita et al. 2004). 
AcPepA has proved to be effective in a pilot primate endotoxin shock model (Okada et al. 
2011). 
The major findings of Study II are that the early inhibition of complement C5a with 
AcPepA effectively restored the impaired LV function and pulmonary circulation in the post-
tamponade period. More importantly, these responses were associated with significant 
decreases in the plasma levels of troponin-T, TNF-α, histamine and complement activation in 
the tissues after the relief of the cardiac tamponade. 
In a relevant study, a significantly increased level of C5a was demonstrated at the 
beginning of reperfusion, followed by a sudden decrease. The harmful consequences are 
evoked during this short, but decisive period (Eppinger et al. 1997). The relatively short 
biological half-life (around 30 min) of AcPepA supports the application of this peptide in this 
time frame. In this line, the study was designed to investigate the effects of a single 
administration, since its major effects were expected at the very beginning of the 
reoxygenation. Our IHC examination data clearly revealed that the timing of AcPepA 
treatment in our pig model was effective, with a decreased level of C3 positivity in the 
AcPepA-treated tamponade group. These early effects may result in further, longer-term 
alterations, but as a first step we aimed to identify the key factors in the acute phase of central 
circulatory failure. 
After the relief of the cardiac tamponade, the MAP remained at a decreased level, 
while the CO did not show any significant differences relative to the control group. This was 
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due to the elevated HR, which is indicative of the increased strain of the heart muscle. 
Following AcPepA treatment, the MAP was elevated to the control level and the CO was also 
maintained. Thus, the most pronounced differences between the compensatory mechanisms of 
the AcPepA-treated and non-treated tamponade groups were the restored MAP and the lower 
HR. This seems to be especially crucial if we consider the fact that the circulation of the heart 
muscle is provided during the diastolic phase, and nearly stops during systole. If the HR is 
increased, the length of the systole does not change, while the diastole is shortened. The 
higher the frequency, the shorter the time available for oxygen delivery to the cardiac muscle 
cells, and therefore a lower HR and maintained CO provide better oxygenation for the heart. 
The elevated GEDV in the treated group also indicates that the main compensatory 
mechanism in this early phase is switched from an increased afterload to an elevation of the 
preload.  
It could be supposed that improvements of the LV function and pulmonary circulation 
play a decisive role in the background of this process. It has been demonstrated that elevation 
of the PVR reduces the CO, because of the increase in RV afterload leading to an impaired 
LV function (Avontuur et al. 1998). However, a well-timed treatment with AcPepA resulted 
in decreases in PAP and PVRI, which contributed to the normalizing of LHEDV. 
In order to determine the effects of C5a antagonist treatment, we had to consider and 
rule out artificial influences which may originate from the experimental design. We therefore 
applied standard fluid replacement therapy in all groups to exclude the effects of the volume 
status on the macrohaemodynamic parameters. In this line, the favourable haemodynamic 
changes might be consequences of the reduced biomarker release (TNF-α, histamine and 
troponin-T) in the post-tamponade phase after AcPepA treatment. 
It has been shown that histamine release is induced by a hypoxic condition (Boros 
2003) and complement C5a has a direct role in this histamine release from mast cells (El-Lati 
et al. 1994). An elevated histamine level in the plasma may lead to enhanced vascular 
permeability and a relative blood loss into the dilated vessels, as can occur in the pulmonary 
circulation in association with the increase in EVLWI (Walkenstein et al. 1985). On the other 
hand, the elevation in plasma histamine level in the early post-tamponade phase shows that 
this level is higher in the portal venous blood than in the arterial blood (Kaszaki et al. 1989). 
It can decrease the peripheral resistance in patients with circulatory shock (Nagy et al. 1986), 
while in the splanchnic area histamine release probably plays a role in the counter-regulation 
of the excessive, prolonged vasoconstriction that contributes to the lethal outcome (Kaszaki et 
 42 
al. 1989). In the presence of AcPepA, the extent of histamine release was reduced, and this 
effect too can contribute to the increased venous return. 
There is increasing evidence that cytokines in general and TNF-α in particular play an 
important role in cardiovascular diseases. Thus, increased levels of TNF-α or of its soluble 
receptors have been implicated in the pathophysiology of ischaemia-reperfusion injury, 
myocarditis, and the progression of congestive heart failure. TNF-α modulates the two most 
important haemodynamic determinants of the cardiac function: the peripheral resistance and 
the cardiac contractility. As concerns the latter, TNF-α could be responsible for a negative 
inotropic effect, by altering intracellular Ca2+ homoeostasis and possibly by inducing NO 
synthesis, which likewise reduces myocyte contractility (Ferrari et al. 1999). An increased 
expression of TNF-α has been demonstrated in a case where infection of the myocardium with 
Influenza A virus was associated with cardiac tamponade, as a potentially fatal complication 
(Mamas et al. 2007). Our experimental data confirm that an acute cardiac tamponade induces 
TNF-α release directly, whereas the administration of AcPepA significantly limits its release. 
Plasma troponin-T is an indirect, but highly sensitive marker of cardiac tissue 
ischaemia and has been used to demonstrate the ischaemic effect of a cardiac tamponade 
(Kelley et al. 2009). The lower level of troponin-T following the relief of the cardiac 
tamponade in the AcPepA-treated tamponade group could be a multiple result of the 
inhibition of the complement system. 
In conclusion, these results demonstrate the relative significance of complement 
activation in the acute circulatory complications of a cardiac tamponade, and the potential role 
of C5a antagonism to reduce inflammatory signals which are important components in the 
development of disturbances of the LV function and the pulmonary circulation. 
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6. SUMMARY OF NEW FINDINGS 
I. We have used a clinically relevant large animal model to study the haemodynamic and 
inflammatory changes caused by a cardiac tamponade. A cardiac tamponade induced 
significant deteriorations of the intestinal macro- and microcirculations, together with 
impairments of the LV function and pulmonary circulation, associated with potentially 
harmful inflammatory consequences in the post-tamponade phase. 
II. Definite signs of inflammatory activation were observed with the release of vasoactive 
and pro-inflammatory mediators, including histamine, big-ET, HMGB-1 and the 
complement system. Influencing these reactions could possibly offer adjuvant 
therapeutic targets through which to decrease the complications of cardiogenic shock 
induced by tamponade. 
III. Via early therapeutic interventions targeting the inhibition of complement C5a with 
AcPepA, the secondary detrimental circulatory consequences of the cardiac 
tamponade can be dampened or reversed. 
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